cresence AS

Biotech

CRES101 and CRES102 are novel and specific biotechologies for treatment of neurodegenerative disorders.

Lead products CRES101 and CRES102 are derived from Epidermal Growth Factors (EGF).
CRES101 and CRES102 act via macrophage M2 polarization as in other therapeutic indications.

Precursor CRES101 (EFG) induces positive response in Experimentals models of Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Drug target characterization and validation: CIDP, CBS, Progressive Multiple Sclerosis and Alzheimer’s disease.
CRESENCE AS pipeline aims at strengthening the offert of innovative therapeutic solutions for neurodegenerative disorders.

Background

epidermical growth factor, cresence AS

technology

macrophage polarization , cresence AS

Scientific evidence

LMOG-induced EAE experiment shows a positive response with EGF administered every other day
versus a reference corticoid derived treatment.
section of midol cord 1
section of midol cord 2
MOG-induced EAE mouse brain with clear signs of remyelination when treated with EGF
(luxol fast blue stained sections of spinal cord).

indications

cidp disease, cresence AS

chronic inflammatory demyelinating polyneuropathy (CIDP) - Orphan disease

CIDP presents with multifocal inflammation and demyelinating lesions of the proximal peripheral nervous system.
From a pathological and clinical standpoint, CIDP has numerous analogies with MS: progressive and relapsing forms of CIDP are also observed.
gbs disease, cresence AS

Guillain Barré Syndrome (GBS) - orphan disease

GBS is an acute form of CIDP and an immune condition, often following an infection.
Nerve lesions marked by demyelination are the pathological hallmarks.

multiple sclerosis, cresence AS

Multiple Sclerosis progressive forms (ms) - rare disease

Myelin continually degrades leading to axon degeneration and neuronal death.
Neurodegeneration is responsible for the chronic disability and progression of MS.
Current treatments for MS rely on immunosuppression with little action, if not on neuroprotection: progressive forms are hardly treated.

alzheimer disease, cresence AS

Alzheimer disease

Alzheimer’s is a neurodegenerative disease in which protein deposits form amyloid plaques and tau tangles in the brain: neurons stop functioning, lose connections and die; the brain shrinks dramatically.
The disease begins with memory impairment; evolution progressively leads to communication problems, addiction and eventually death.
There is no disease-modifying treatment. Only symptomatic treatments somehow delay progression.

pipeline

cresence AS, pipeline
Currently the pipeline is in a preclinical phase, but should advance as quickly as possible towards the first human administration.